Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2006, Vol. 11 ›› Issue (2): 136-140.
Previous Articles Next Articles
WU Jin-shou, HONG Hua-shan
Received:
2005-10-12
Revised:
2005-12-22
Online:
2006-02-06
Published:
2020-10-26
CLC Number:
WU Jin-shou, HONG Hua-shan. Relationship between hypertension and inflammation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(2): 136-140.
1 | Badr K, Wainwright CL. Inflammation in the cardiovascular sys- tem : here, there and everywhere[ J] . Curr Opin Pharmacol, 2004; 4: 107-9 |
2 | Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospectivestudy of C-reactive protein and the risk of future car- · 138 · Chin J Clin Pharmacol Ther 2005diovascular eventsamong apparently healthy women[ J] .Circula- tion, 1998; 98: 731 -3 |
3 | Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM.C- reactiveprotein, IL 6, and risk of developing type 2 diabetes mellitus[ J] .JAMA Assoc, 2001 ; 286: 327-34 |
4 | Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuo- mainen TP, Valkonen VP, et al .C-reactive protein and the development of the metabolic syndrome and diabetes in middle- aged men[ J] .Diabetologia, 2004; 47 : 1403-10 |
5 | Panza JA, Quyyumi AA, Brush JE, Epstein SE.Abnormal en- dothelium dependent vascular relaxation in patients with essential hypertension[ J] .N Engl J Med, 1990;323 : 22-7 |
6 | Linder L, Kiowski W, Buhler FR, Luscher TF.Direct evidence for release of endothelium-derived relaxing factor in human fore- arm circulation in vivo.Blunted responses in essential hyperten- sion[ J] .Circulation, 1990;81 :1762-7 |
7 | Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ .Ab- normal edothelium-dependent coronary vasomotion in hypertens- ive patients[ J] .J Am Coll Cardiol, 1992;19 : 809-15 |
8 | Lo pez-Jaramillo P.Calcium, nitric oxide, and preeclampsia [ J] .Seminars Perinatol, 2000;24 : 33-6 |
9 | Schmid-Schonbein GW, Seiffge D, Delano FA, et al .Leuko- cyte counts and activation in spontaneously hypertensive and nor- motensive rats[ J] .Hypertension, 1991; 17: 323 -30 |
10 | McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM . Monocyte adhesion to cerebromicrovascular endothelial cells de- rived from hypertensive and normotensive rats[ J] .Am J Physi- ol, 1994; 267 :H2491 -7 |
11 | Bataillard A, Renaudin C, Sassard J.Silica attenuates hyper- tension in Lyon hypertensive rats[ J] .J Hypertens, 1995;13 : 1581-4 |
12 | Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, et al .Preactivation peripheral blood monocytes in patients with essential hypertension[ J] . Hypertension, 1999 ; |
34 | : 113-7 |
13 | Chae CU, Lee RT, Rifai N, Ridker PM.Blood pressure and inflammation in apparently healthy men [ J] .Hypertension, 2001; 38 : 399-403 |
14 | Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM . In- terrelationships among circulating interleukin-6, C-reactive pro- tein, and traditional cardiovascular risk factors in women[ J] . Arterioscler Thromb Vasc Biol, 2002; 22: 1668 -73 |
15 | Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[ J] .N EnglJ Med, 2000;342 : 836 -43 |
16 | Teran E, Escudero C, Moya W, Flores M, Vallance P, López- Jaramillo P.Markers of chronic inflammation in normal pregnan- cy and pre-eclampsia[ J] .Br J Obstet Gynecol, 2000 ; 17: 201- 8 |
17 | Festa A, D' Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM.Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin resistance atherosclero- sis study ( IRAS) [ J] .Circulation, 2000 ; 102: 42-7 |
18 | Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI.Is C-reactive protein an independent risk factor for essential hypertension[ J] ? J Hypertens, 2001 ; 19 : 857 -61 |
19 | Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al .Increased C-reactive protein concentrations in never-treated hypertension : the role of sy stolic and pulse pre- ssures[ J] .J Hypertens, 2003 ; 21: 1841-6 |
20 | Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM.C-reactive protein and the risk of developing hypertension [ J] .JAMA, 2003; 290 : 2945 -51 |
21 | Bautista LE, Vera LM, Arenas IA, Gamarra G.Independent association between inflammatory markers ( C-reactive protein, interleukin-6, and TNF-α ) and essential hypertension [ J] . J Hum Hypertens, 2005; 19: 149 -54 |
22 | Weber KT, Pick R, Jalim JE.Patterns of myocardial fibrosis [ J] . J Mol Cell Cardiol, 1989 ; 21: 11-23 |
23 | Hinglais N, Heudes D, Nicoletti A.Colocalization of myocardi- al fibrosis and inflammatory cells in rats[ J] .Lab Invest, 1994; 70: 286-94 |
24 | Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB.Inflammatory cells and myocardial fibrosis :spatial and temporal distribution in renovascular hypertensive rats[ J] . Cardiovasc Res, 1996; 32 :1096-107 |
25 | Nicoletti A, Michel JB .Cardiac fibrosis and inflammation: in- teraction with hemodynamic and hormonal factors[ J] .Cardio- vasc Res, 1999; 41:532 -43 |
26 | Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, et al .Hypertensive myocardial fibrosis and diastol- ic dysfunction :another model of inflammation[ J] .Hyperten- sion, 2004 ; 43: 739-45 |
27 | Patella V, Marino I, Lamparter B, Arbustini E, Adt M, Marone G.Human heart mast cells.Isolation, purification, ul- trastructure, and immunologic characterization[ J] . J Immunol, 1995; 154:2855-65 |
28 | Frangogiannis NG, Burns AR, Michael LH, Entman ML.His- tochemical and morphological characteristics of canine cardiac mast cells[ J] .Histochem J, 1999; 31 : 221-9 |
29 | Kato HN, Hirano S, Yasuno H .Solitary mastocytoma treated with tranilast[ J] . J Dermatol, 1996 ; 23: 335-9 |
30 | Dickhout JG, Lee RM . Structural and functional analysis of ar- teries from young spontaneously hypertensive rats[ J] . Hyperten- sion, 1997 ; 29: 781-9 |
31 | Intengan HD, Schiffrin EL.Vascular remodeling in hyperten- sion: roles of apoptosis, inflammation, and fibrosis[ J] . Hyper- tension, 2001 ; 38: 581-7 |
32 | Virdis A, Schiffrin EL.Vascular inflammation:a role in vascu- lar disease in hypertension[ J] .Curr Opin Nephrol Hypertens. 2003; 12: 181 -7 |
33 | Luvara G, Pueyo ME, Philippe M, Mandet C, Savoie F, Hen- rion D, et al . Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall :prevention by angiotensin II antagonism[ J] .Arterioscler Thromb Vasc Biol, 1998; 18: 1408 -16 |
34 | Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al .PPARa activator effects on Ang II-induced vascular 中国临床药理学与治疗学 2005 · 139 ·oxidative stress and inflammation[ J] .Hypertension, 2002 ;40 : 866 -71 |
35 | Touyz RM.Intracellular Mechanisms Involved in Vascular Re- modeling of Resistance Arteries in Hypertension:Role of Angio- tensin II[ J] . Exp Physiol, 2005 ; 12: ( Epub ahead of print) |
36 | Touyz RM.Oxidative stress and vascular damage in hyperten- sion[ J] . Curr Hyperten Rep, 2000; 2:98 -105 |
37 | Suematsu M, Suzuki H, DeLano FA, Schmid-Schonbein GW. The inflammatory aspect of the microcirculation in hypertension : oxidative stress, leukocytes endothelial interaction, apoptosis [ J] .Microcirculation, 2002 ; 9: 259 -76 |
38 | Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB.Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation in- duced by intracellular oxidative stress[ J] .Arterioscler Thromb Vasc Biol, 2000; 20: 645-51 |
39 | Touyz RM.Molecular and cellular mechanisms in vascular inju- ry in hypertension:role of angiotensin II[ J] . Curr Opin Nephrol Hypertens, 2005; 14: 125 -31 |
40 | Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al .Kjeldsen SE, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Tria l - Lipid Lowering Arm ( ASCOT-LLA) :amulticentre randomized controlled trial[ J] . Lancet, 2003;361 : 1149-58 |
41 | Blanco-Colio LM, Osende JI, Martin-Ventura JL, Tunon J, Egido J .Statins in hypertensive patients:potential explanations for the ASCOT-LLA study results[ J] .Drugs, 2004 ; 64: 61-7 |
42 | Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A.Associa- tion between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study [ J] .Am Heart J, 2004 ; 148: 285-92 |
[1] | LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978. |
[2] | ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840. |
[3] | NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467. |
[4] | SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120. |
[5] | FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876. |
[6] | LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng. Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753. |
[7] | CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774. |
[8] | MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan. Oral lienal peptides improve ammonia-induced coughing and inflammation in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607. |
[9] | JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan. Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631. |
[10] | CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408. |
[11] | ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422. |
[12] | CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427. |
[13] | LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432. |
[14] | XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441. |
[15] | KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||